sorafenib has been researched along with Myeloproliferative Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dhangar, S; Ghatanatti, J; Mathan S, LP; Sawant, L; Shah, A; Shanmukhaiah, C; Vundinti, BR | 1 |
| Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D | 1 |
| Falchi, L; Lu, G; Luthra, R; Lyle, LM; Mehrotra, M; Newberry, KJ; Patel, KP; Popat, U; Verstovsek, S | 1 |
| Chang, E; Foerster, S; Gondek, L; Huso, DL; Levis, M; Li, L; Lim, Y; Ma, H; Marchionni, L; Matsui, W; McGovern, K; Merchant, AA; Peacock, CD; Small, D; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Aberg, E; Duyster, J; Engh, RA; Gorantla, SP; Oliveira, TM; Peschel, C; Thöne, S; von Bubnoff, N | 1 |
| Chen, W; Collins, R; Tirado, CA; Wakim, JJ | 1 |
1 review(s) available for sorafenib and Myeloproliferative Disorders
| Article | Year |
|---|---|
t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature.
Topics: Antineoplastic Agents; Benzenesulfonates; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Diagnosis, Differential; Humans; Myeloproliferative Disorders; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcr; Pyridines; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Translocation, Genetic | 2011 |
5 other study(ies) available for sorafenib and Myeloproliferative Disorders
| Article | Year |
|---|---|
Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement.
Topics: Azacitidine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Translocation, Genetic | 2023 |
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured | 2013 |
ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.
Topics: Adult; Cytogenetics; Eosinophilia; ETS Translocation Variant 6 Protein; Female; fms-Like Tyrosine Kinase 3; Humans; Mutation; Myeloproliferative Disorders; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ets; Repressor Proteins; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2014 |
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
Topics: Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Myeloproliferative Disorders; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Sorafenib; STAT5 Transcription Factor; Stem Cells; Veratrum Alkaloids; Zinc Finger Protein Gli2 | 2015 |
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
Topics: Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Myeloproliferative Disorders; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Structure-Activity Relationship | 2011 |